Boston Scientific Corporation $BSX Shares Purchased by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 0.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,760 shares of the medical equipment provider’s stock after acquiring an additional 259 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Boston Scientific were worth $3,304,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after acquiring an additional 21,173 shares during the period. Highview Capital Management LLC DE lifted its holdings in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after acquiring an additional 1,439 shares during the period. Gotham Asset Management LLC lifted its holdings in Boston Scientific by 43.7% in the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider’s stock valued at $1,021,000 after acquiring an additional 3,475 shares during the period. Finally, Man Group plc lifted its holdings in Boston Scientific by 30.1% in the fourth quarter. Man Group plc now owns 271,059 shares of the medical equipment provider’s stock valued at $24,211,000 after acquiring an additional 62,662 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.6%

Boston Scientific stock opened at $102.71 on Friday. The stock has a market cap of $152.19 billion, a PE ratio of 61.14, a P/E/G ratio of 2.51 and a beta of 0.65. The stock has a 50-day moving average price of $104.86 and a 200 day moving average price of $102.26. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on BSX shares. UBS Group raised their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research note on Thursday. Morgan Stanley lifted their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, May 16th. Citigroup reaffirmed a “buy” rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $118.04.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.